The Thyroid Gland Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Thyroid Gland Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Thyroid Gland Disorders. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thyroid Gland Disorders and features dormant and discontinued products.

GlobalData tracks 28 drugs in development for Thyroid Gland Disorders by 28 companies/universities/institutes. The top development phase for Thyroid Gland Disorders is preclinical with 11 drugs in that stage. The Thyroid Gland Disorders pipeline has 28 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Thyroid Gland Disorders pipeline products market are: HanAll Biopharma, MyMD Pharmaceuticals and Crinetics Pharmaceuticals.

The key targets in the Thyroid Gland Disorders pipeline products market include Thyrotropin Receptor (Thyroid Stimulating Hormone Receptor or TSHR), Thyroid Hormone Receptor Alpha (Nuclear Receptor Subfamily 1 Group A Member 1 or V erbA Related Protein 7 or c erbA 1 or c erbA Alpha or EAR7 or THRA), and Thyroid Hormone Receptor Beta (Nuclear Receptor Subfamily 1 Group A Member 2 or c erbA 2 or c erbA Beta or ERBA2 or THRB).

The key mechanisms of action in the Thyroid Gland Disorders pipeline product include Thyrotropin Receptor (Thyroid Stimulating Hormone Receptor or TSHR) Antagonist with five drugs in Phase I. The Thyroid Gland Disorders pipeline products include eight routes of administration with the top ROA being Oral and eight key molecule types in the Thyroid Gland Disorders pipeline products market including Small Molecule, and Monoclonal Antibody.

Thyroid Gland Disorders overview

Thyroid gland disorders are conditions that affect the function of the thyroid, a butterfly-shaped gland in the front of the neck. The thyroid produces hormones that regulate metabolism, growth, development and body temperature. Some of the common thyroid disorders are hypothyroidism, goiter, hyperthyroidism, and thyroid cancer. Thyroid disorders can be diagnosed by blood tests that measure the levels of thyroid hormones and thyroid-stimulating hormone (TSH). Treatment depends on the type and severity of the disorder and may include medication, surgery, radioactive iodine, or hormone replacement therapy.

For a complete picture of Thyroid Gland Disorders’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.